Embryonal carcinoma (EC) cells, the stem cells of teratocarcinomas, are the malignant counterparts of pluripotent embryonic stem (ES) cells, but commonly exhibit a reduced ability to differentiate, presumably because of continual selection for genetic changes that alter the balance between self-renewal, differentiation and apoptosis in favour of self-renewal. To explore the nature of the genetic changes that promote nullipotency, we have compared two human EC cell lines, a 'nullipotent' line, 2102Ep, and a 'pluripotent' line, NTERA2. A hybrid derived by fusion of these cells differentiates in response to retinoic acid but, unlike the parental NTERA2 line, does not form terminally differentiated neurons. This implies that the nullipotent EC cell line, 2102Ep, differs in expression of at least two functions in comparison with the NTERA2 pluripotent line, one affecting commitment to differentiation, and one affecting terminal neural differentiation. We have now investigated the possible role of the CDK inhibitor, p27 kip1 (p27) in commitment and terminal differentiation. In NTERA2, but not in 2102Ep cells, retinoic acid induces up-regulation of p27 expression, suggesting that 2102Ep cells lack this capacity. However, constitutive expression of a p27 transgene does not overcome the block to differentiation in the 2102Ep parental cells; commitment to differentiation must be blocked elsewhere. On the other hand, constitutive over-expression of p27 from a transgene enhances the neural differentiation of NTERA2 cells. Our results suggest that p27 plays a role in terminal neuronal differentiation of human EC cells, but not in their initial commitment to differentiation, and that other factors, possibly Cyclin D2, specifically limit its ability to promote neural differentiation. q
Introduction
Teratocarcinomas, a subset of germ cell tumours (GCT), may contain a wide array of somatic and extraembryonic differentiated cells, together with their undifferentiated embryonal carcinoma (EC) stem cells (O'Hare, 1978) . Human EC cells closely resemble human embryo-derived embryonic stem (ES) cells, as well as cells of the inner cell mass (ICM) from early human embryos at the blastocyst stage Henderson et al., 2002) . Thus, EC cell lines provide tools for investigating the regulation of cell differentiation during human embryogenesis, as well as the histiogenesis of GCT (Pierce, 1975) .
EC cells are highly malignant and are important contributors to the malignancy of the GCT in which they occur. However, their differentiated derivatives tend to have a limited capacity for proliferation or for forming invasive tumours. Consequently, any genetic changes that reduce the capacity of EC cells to differentiate would provide such cells with a strong selective advantage during tumour progression. Indeed, a significant proportion of human GCT contains EC elements but relatively little or no somatic tissue (Looijenga and Oosterhuis, 2002) . Further, many EC cell lines derived from such tumours show little, or no, capacity for differentiation (Andrews, 1998) . Recently, we have noted that initially diploid human ES cells adapt progressively to culture by acquiring karyotypic changes that resemble those seen in EC cells (Draper et al., 2004) . Those results highlight a likely relationship between culture adaptation of human ES cells and tumour progression of their malignant EC counterparts. However, the nature of the genetic changes that underlie such progression and lead to an eventual loss of pluripotency is obscure.
Human GCT are characterised by the frequent amplification of the short arm of chromosome 12 (12p), usually in the form of one or more isochromosomes (12p) (Atkin and Baker, 1982; Mostert et al., 1996; Sandberg et al., 1996) , and of the long arm of chromosome 17 (17q) (Kraggerud et al., 2002) . A number of candidate genes that might play a role in this selection have been identified on chromosomes 17q and 12p. They include genes encoding STAT3 and Grb2 (Burdon et al., 2002) , and Grb7 on chromosome 17q, and Nanog (Chambers et al., 2003) , Cyclin D2 and p27 kip1 (Hoglund et al., 1996) , on chromosome 12p.
In another study, we had investigated the behaviour of hybrid cells produced by fusing a pluripotent human EC cells from the NTERA2 line with nullipotent human EC cells from the 2102Ep line (Duran et al., 2001 ). NTERA2, but not 2102Ep, EC cells differentiate in response to retinoic acid, producing neurons as well as a range of other cell types (Andrews, 1984; Andrews et al., 1982; Matthaei et al., 1983) . Nevertheless, 2102Ep cells are able to respond to retinoic acid as indicated by their induction of directly retinoic acid-responsive genes, such as RARb. The hybrid NTERA2!2102Ep cells also exhibit an EC phenotype: like their NTERA2 parent, they differentiate in response to retinoic acid, and also when they form xenograft tumours in SCID mice (Duran et al., 2001) . This suggested the hypothesis that, during tumour progression, EC cells in the tumour from which the 2102Ep line was derived had lost a key function necessary for commitment to differentiation but that this function was retained by NTERA2 EC cells. On the other hand, although the hybrid cells were able to differentiate, they did not yield neurons, which are a typical feature of retinoic acid-induced NTERA2 differentiation. This further suggested that the 2102Ep cells provide the hybrid cells with a function that inhibits this final step in neural differentiation. In other words, the control of commitment to differentiation and of terminal differentiation in specific lineages involve separable functions.
One group of molecules that are known to regulate cell differentiation and may be targets for mutations that interfere with differentiation are the proteins that control the G1:S phase transition of the cell cycle. They include Cyclins D, E, and A, which function together with their specific kinases, CDK4, CDK6, and CDK2 (Boonstra, 2003; Lee and Yang, 2003) . This checkpoint is also negatively regulated by two families of kinase inhibitors, INK4 (p15, p16, p18, and p19) and Cip/Kip (p21, p27, and p57). These proteins can act as tumour suppressors or oncogenic factors, and disruption at the G1:S checkpoint contributes to development of many tumours (Hall and Peters, 1996) . Of these various regulatory proteins operating at the G1:S phase boundary, low levels of p27 expression are associated with a high degree of aggressiveness of many malignant tumours (Alkarain et al., 2004; Slingerland and Pagano, 2000) . Further, p27 and Cyclin D2 are encoded by genes located on chromosome 12p (Hoglund et al., 1996) . Given the association of chromosome 12p amplification with GCT progression, we have now tested whether p27 plays a role in regulating the differentiation of EC cells and might contribute to the different behaviours of the pluripotent and nullipotent NTERA2 and 2102Ep human EC cells.
Results

p27 expression in response to retinoic acid and proteasome inhibitor
The level of cellular p27 protein is thought to depend upon control of its degradation in proteasomes following ubiquitination, and it has been suggested that retinoic acid may influence differentiation, at least in part, by inhibiting the proteasome-related degradation of p27 (Baldassarre et al., 2000; Borriello et al., 2000; Dimberg et al., 2002; Pagano et al., 1995) . To test whether a defect in such retinoic acid-induced stabilization of p27 might underlie the failure of 2102Ep EC cells to differentiate, we first examined the effects of the proteasome inhibitor, carbobenzoxy-L-leucyl-L-leucinal (MG-132) and retinoic acid on p27 levels in NTERA2, 2102Ep, and the C10 hybrid cells. In all three lines, the proteasome inhibitor caused a modest increase in levels of p27, assayed 7 days after initial exposure ( Fig. 1) , suggesting that proteasome regulation of p27 is functional in each line. Retinoic acid itself also caused an increase in p27 levels after 7 days in NTERA2 and C10 cells, but had no significant effect on levels of p27 in 2102Ep cells. Thus, if regulation of proteasome function by retinoic acid does play a role in its induction of EC cell differentiation, these data are consistent with a hypothesis Fig. 1 . Western blot analysis of p27 protein in three different cell lines, in response to the proteasome inhibitor MG-132 (carbobenzoxy-L-leucyl-Lleucinal) (PI) (10 nM) and retinoic acid (RA) (10 K5 M). The cells were cultured in the presence of PI or RA for 7 days. Note that exposure to PI induces p27 protein level in all EC cells, while retinoic acid increases p27 only in pluripotent cells of NTERA2 and Cl0. that dysfunction of retinoic acid dependent control of proteasome activity could underlie its inability to induced differentiation of 2102Ep cells. Alternatively, increased levels of p27 in RA-induced NTERA2 and C10 but not 2102Ep cells may simply be a consequence rather than cause of their differentiation.
Repression of cell cycling in response to p27 over-expression
To investigate this further we transfected NTERA2, C10, and 2102Ep cells with a vector driving constitutive expression of p27. Several independent transgenic clones were produced from each parental cell line. The transgenic clones of NTERA2, C10, and 2102Ep were labelled as NT2-p27/A, NT2-p27/B, NT2-p27/C, etc.; C10-p27/A, C10-p27/B, C10-p27/C, etc.; and 2102-p27/A, 2102-p27/B, 2102-p27/C, etc., respectively. For further analysis, three stably transfected clones of each line were selected. These all expressed significantly higher levels of p27 than the untransfected cells, when examined by RT-PCR and Western blotting (Fig. 2) . As anticipated from the role of p27 regulating the G1:S boundary of the cell cycle, each clone expressing constitutively higher levels of p27 exhibited a significant reduction in growth rate compared to the parental, non-transfected cell line (Fig. 3) . We also tested BrdU incorporation into the cells and used this to estimate the potential doubling times of the non-transfected and transfected cells (Fig. 4) . In each case, the transfected cells exhibited an increase in potential doubling time of about 8 h, indicating that the p27 transgene is, indeed, functional.
Since p27 is a well known to affect the cell cycle by binding to CDK2 and inhibiting progression of G1-S transition, we also examined the effect of the p27 transgene on the expression of Cyclin D2 and Cyclin E, two cyclins active at the G1:S boundary. Specifically, we observed that the constitutive expression of p27 resulted in an up-regulation of Cyclin D2 expression, but had no effect on Cyclin E (Fig. 5 ).
Differentiation of human EC cells expressing p27 transgene
To test whether constitutive expression of p27 itself results in differentiation or whether it influences differentiation induced by retinoic acid, the expression of differentiation antigens by two of the p27 transfected clones of each line was examined in comparison to the parent lines (Fig. 6 ). In the transfected NTERA2 and C10 lines, in the absence of retinoic acid, we did observe some reduction Fig. 2 . Expression of p27 in NTERA2, 2102Ep, and C10 hybrid EC cells transfected with a vector encoding p27. Equal amount of soluble protein was loaded on SDS gel and the level of p27 was analysed in the p27 overexpressing lines and their controls. Three independent transgenic clones of each parental cell were analysed in this experiment. in the expression of SSEA3, a characteristic surface antigen marker of undifferentiated human EC cells. There was also small increases in expression of A2B5 and VINIS56, ganglioside antigens associated with neural differentiation (Andrews, 1984; Andrews et al., 1990) ; this was most noticeable with respect to VINIS56 (Fig. 6B ). These observations suggest that the over-expression of p27 in these cells did promote some degree of spontaneous differentiation of the pluripotent EC cells. However, there was no significant effect on the expression of these antigens by 2102Ep cells.
After treating the untransfected cells with retinoic acid for 7 days, as anticipated, the expression of SSEA3 was markedly reduced, and the expression of SSEA1, A2B5, and VINIS56 was induced in NTERA2 and C10 but not in 2102Ep cells, although a small reduction in SSEA3 expression in untransfected 2102Ep cells was noted. However, by comparison, the induction of A2B5 and VINIS56 by retinoic acid in the transfected NTERA2 and C10 cells was significantly stronger. On the other hand, the presence of p27 had no effect on the lack of induction of these antigens by retinoic acid in 2102Ep cells. Thus, while constitutive expression of p27 appeared to enhance the differentiation of NTERA2 and C10 cells following retinoic acid induction, as indicated by expression of these marker antigens, it was not sufficient to overcome the nullipotency of 2102Ep cells.
Increased neural differentiation in retinoic acid treated pluripotent cells with high p27
The two differentiation antigens, A2B5 and VINIS56, are ganglioseries glycolipids (GT3 and GD3, respectively) and are associated with the neural lineage (Andrews et al., 1990; Fenderson et al., 1987) . Previously, we had failed to find neural differentiation in C10 hybrid cells, even though they appeared otherwise to differentiate in response to retinoic acid like NTERA2 cells (Duran et al., 2001) . Therefore, we investigated further the extent of neuronal differentiation in the transfected cells. No evidence of neural differentiation induced by retinoic acid was detected in cultures of the 2102Ep cells whether or not they had been transfected to express p27 (data not shown). On the other hand, although neurons were observed after retinoic acid induction of NTERA2 cells, as previously described (Fig. 7A) , it was striking that they appeared in substantially greater numbers in NTERA2 cells constitutively expressing p27 (Fig. 7B) . Since it is difficult to count neurons directly, we confirmed this observation by analysis of expression of the neuronal gene encoding the neurofilament heavy chain, NEFH (Fig. 8) . After retinoic acid induction, substantially increased expression of the NEFH gene was observed in the NTERA2 cells constitutively expressing p27 compared to the parental line.
Even more striking, however, was the appearance of neurons in retinoic acid-induced cultures of C10 constitutively expressing p27, whereas no neurons were observed in the untransfected C10 line (Fig. 7C) . Taken together, these results indicate that a failure to induce p27 is not the underlying cause of nullipotency and failure of 2102Ep cells to differentiate in response to RA, but that p27 does play a role in the terminal differentiation of EC cells, especially into neurons.
Discussion
The differentiation of pluripotent stem cells may be broken into two distinct phases, of commitment and terminal differentiation. Only the latter is associated with exit from the cell cycle. For example, during the differentiation of NTERA2 cells induced by retinoic acid, most cells commit to differentiate within 24 h of exposure, and lose typical EC markers (e.g. the surface antigen SSEA3) within 7 days of induction; but a substantial population of cells cycling at about the same rate as the undifferentiated, uncommitted EC cells persists in the cultures for at least 3 weeks, during which time terminal neural, and other differentiation also occurs (Andrews, 1984; Mavilio et al., 1988) . Thus differentiation involves both the production of proliferating 'committed' cells, as well as terminal differentiated cells that no longer divide, such as neurons.
The evolution of nullipotent variants from pluripotent stem cells could involve blocks to either of these steps, or both. The behaviour of the hybrid cells produced between, respectively, pluripotent and nullipotent human EC cell lines, NTERA2 and 2102Ep, suggests that the nullipotent cells contain multiple blocks to differentiate both at the point of commitment and in relation to terminal differentiation. Evidently, the failure of 2102Ep cells to commit to differentiate involves loss of some key function, since the defect is complemented in the hybrid cells, which are able to differentiate. On the other hand, in relation to terminal differentiation the 2102Ep cells must express a function that inhibits neural differentiation, as evidenced by the failure of the C10, NTERA2!2102Ep, hybrid cells to differentiate into neurons (Duran et al., 2001 ). However, whatever the nature of that inhibitory activity, it must also be lineage specific since terminally differentiated cell types of other lineages (e.g. cartilage) are formed by the hybrid cells.
From our present results, it appears that 2102Ep nullipotent cells carry a defect in regulation of p27, since treatment with retinoic acid did not cause an up-regulation of p27 protein levels, which does occur in the NTERA2 and C10 cells. On the other hand, the proteasome system for degradation of p27 is evidently functioning in all three cell lines. Since retinoic acid receptors and proteasome regulation of p27 are both functional in 2102Ep cells, the results suggest a defect lies in the mechanisms linking retinoic acid response and proteasome activity. This defect in the linking mechanism is likely to represent the lack of a key function as it is complemented in the hybrid C10 cells which do respond to retinoic acid by up-regulating p27 levels. Nevertheless, this apparent lack in p27 regulation in 2102Ep cells is not the underlying cause of the nullipotency of 2102Ep cells since constitutive expression of p27 at high levels was not, of itself, sufficient to make 2102Ep cells permissive for any differentiation.
However, constitutive expression of p27 in the transfected NTERA2 cells did enhance their capacity for neural differentiation, while it permitted neurogenesis in the C10 hybrid cells in which it was not previously seen. Taken together the results suggest that, in the hybrids, the 2102Ep genome had introduced a function that tends to inhibit p27 activity, since the retinoic acid-induced expression of endogenous p27 in untransfected C10 cells was not of itself sufficient to result in neural differentiation. One possibility is that a factor(s) present in the C10 hybrid cells, introduced from the 2102Ep parent, is sufficient to titrate out the activity of endogenous p27, but not sufficient to titrate out the constitutively produced p27 from the transgene. One candidate for such an activity is Cyclin D2. Over-expression of p27 induced an increased expression of Cyclin D2 mRNA level in all three cell lines, while the level of Cyclin E remained unchanged. This was unexpected, because p27 was thought to exert its inhibitory effect mainly by binding to the Cyclin E-CDK2 complex (Sheaff et al., 1997) . However, a positive correlation between p27 and Cyclin B-type protein levels has also been reported in mouse EC cells (Preclikova et al., 2002) . This result was explained by attributing a possible role for D-type cyclins to sequester p27 and prevent its inhibitory effect towards cell cycle (Bouchard et al., 1999) . Combining this proposal with our observations, it is possible that p27 and Cyclin D2 are involved in a mutual feed back control loop in which Cyclin D2 binds and inhibits p27 activity, while free p27 induces increased expression of Cyclin D2 itself. That both p27 and Cyclin D2 loci are linked on chromosome 12p might have a bearing on this possible feedback loop. The dominant 'neural inhibitory factor' introduced into the C10 hybrid from the 2102Ep parent might therefore be an enhanced ability of Cyclin D2 encoded by the 2102Ep genome to titre out p27 activity, which can only be overcome by high level p27 expression from the transgene in the transfected hybrids. However, it is probably not simply higher levels of Cyclin D2 expression from the 2102Ep genome since we have detected similar Cyclin D2 mRNA levels in all three cell lines. More likely is a mutation affecting its function.
Evidently, the evolution of the nullipotent state in 2102Ep cells has involved the acquisition of multiple genetic changes that influence the ability of the cells both to commit to differentiation, and to undergo terminal differentiation. Some of these changes relate to regulation of the G1:S boundary by Cip/Kip p27, which particularly plays a key role in the terminal differentiation of neural cells from human EC cells. However, this is not true for all lineages since other, non-neuronal differentiated cells are formed by the C10 hybrid cells. Also, dysregulation of p27 does not appear to contribute directly to the control of commitment of the pluripotent stem cell to differentiation.
Experimental procedures
Cell culture and differentiation
Human EC cells, NTERA2 cl.D1 (NT2/D1) and 2102Ep cl.4D3 (Andrews et al., 1982) , and the NTERA2!2102Ep hybrid line, C10 (Duran et al., 2001) , were cultured as previously described in Dulbecco's modified eagles medium (DMEM) supplemented with 10% foetal calf serum (FCS) at 37 8C and humidified 10% CO 2 in the air. For harvesting, NT2/D1 cells were scraped by glass beads; C10 and 2102Ep cells were released by 0.25% trypsin in calcium and magnesium-free Dulbecco's phosphate-buffered saline (PBS), containing 1 mM EDTA. Differentiation was induced with retinoic acid (10 K5 M) (Eastman-Kodak, Rochester, NY) as previously described (Andrews, 1984) . To inhibit proteasome function, cells were exposed to 10 nM of a non-specific proteasome inhibitor of MG-132 (carbobenzoxy-L-leucyl-L-leucinal) (Cat. No. 474790, Calbiochem) in DMSO and harvested as above.
Protein preparation and Western blotting
Cells (5!10 6 ) were lysed in 0.5 ml, ice-cold RIPA buffer (1% NonIdet P-40 (NP-40) or Igepal CA-630, 0.4% sodium deoxycholate, 0.1% SDS), including a mixture of proteinase inhibitors (Complete Mini tablet) (Roche). The lysate was mixed and incubated on ice for 30 min, and further disrupted by sonication, and left for another 30 min on ice. The mix was centrifuged at 10,000!g for 10 min at 4 8C. The protein content of each sample was measured by Bradford protein assay protocol (Bio-Rad Inc.). Soluble protein (15 mg) was electrophoresed on 10% SDS-polyacrylamide gel and blotted onto PVDF membrane (BioRad). The membranes were blocked in PBS with 4% skim milk (blocking solution) for at least 1 h and incubated with p27 polyclonal primary antibody (Novo Castra), diluted 1:200 in blocking solution at 4 8C overnight. The membrane was washed three times in PBS-Tween (0.05% Tween-20 (Sigma) in PBS) and incubated for 40 min in secondary antibody (alkaline phosphatase-conjugated anti-mouse IgG) (Sigma), diluted 1:5000 in the blocking solution. After washing three times as before, the membrane was exposed to the alkaline phosphatase substrate (ECL) (Amersham), for 1 min and exposed to X-ray sensitive film (Konica).
RT-PCR analysis
Total RNA was extracted using Tri-reagent (Sigma) (10 7 cells/ml). To remove any DNA contamination, this RNA was treated with DNase (Ambion) and quantified by spectrophotometery and running on 1% agarose gel. The first strand of cDNA was extended using 5 mg of total RNA and 100 pmol of oligo (dT) primer, 200 units of M-MLV reverse transcriptase (Promega) plus its reaction buffer, and 1.25 mM dNTPs in final volume of 40 ml, followed by 2 h incubation at 37 8C and 5 min inactivation at 80 8C. Onemicrolitre of this reaction mixture was used as template for polymerase chain reaction (PCR) following standard protocols.
Plasmid construction and cell transfection
P27 cDNA was extended by RT-PCR from total RNA of human ES cells, H7 line (Thomson et al., 1998) , using the following primers, which included XhoI and NotI sites in their 5 0 sites, respectively: forward: CTCGAGAAGATGTCAAACGTGAGAG-TGTCTA, and reverse: GACGTCTTTTCATGTATATCTTCCTTGC TTCATAAA
The cDNA was subcloned into the pGEM-T easy vector (Promega), and sequenced to confirm its correct sequence. This vector was digested with XhoI and NotI restriction enzymes and run on 1% agarose gel. The cDNA was gel purified using a DNA gel purification kit (Qiagen) and subcloned between CAG promoter and a puromycin resistant gene in the pCAG-EGFP vector (Niwa et al., 1991) by replacing the GFP gene in the vector. In this vector an IRES sequence linked p27 cDNA to the puromycin resistant gene, to keep co-expression of these two genes. For DNA transfection of the vector, human EC cells were seeded into 3 ml medium at 3!10 4 cells/cm 2 in 6-well plates, 24 h before transfection. 9 mg of the vector was mixed in 300 ml of filter sterilised NaCl (150 mM) and 21 ml ExGen 500 (Fermentas), mixed and added into the culture. The culture was left to grow for another 24 h and the medium was replaced with fresh medium including 0.85 mg/ml puromycin. The medium was changed every 2 days until antibiotic resistant colonies were recovered. Each independent colony of the cells was scraped by sterile glass Pasteur pipette and grown separately for further analysis.
Cell surface antigens
Cell surface antigen assessment was performed as previously described (Andrews, 1984) . Briefly, cells were harvested and incubated in primary antibodies for 1 h at 4 8C. After three washes in wash buffer (5% FCS and 0.02% sodium aside in magnesium and calcium free Dulbecco's phosphate-buffered saline (PBS)), they were incubated in a FITC-conjugated secondary IgG or IgM antibody for 1 h. They were then resuspended in wash buffer and analysed using a Coulter Epics Elite, ESP flow cytofluorimeter. The following antibodies were used: MC631 (anti-SSEA3) , MC480 (anti-SSEA1) (Solter and Knowles, 1978) , A2B5 (anti-ganglioside GT3) (Eisenbarth et al., 1979) and VINIS56 (anti-ganglioside GD3) (Andrews et al., 1990) . The antibody produced from the myeloma P3X63Ag8 (Kohler and Milstein, 1975 ) was used as a negative control.
BrdU incorporation and DNA content assay
Cells (4!10 6 ) were seeded in two separated 75 cm 2 tissue culture flasks and grown for 24 h to reach their exponential growing stage. The medium was replaced by fresh medium containing 200 mM BrdU and incubated for 30 min at 37 8C. This BrdU medium was then discarded and the flasks were washed three times by PBS. Cells of one flask were harvested and fixed with 70% ice-cold ethanol and the second flask was incubated in normal medium for further 4 h at 37 8C, followed by harvesting and fixing in the same way. After fixation, the cells were stained for indirect immunofluorescence with a specific anti-BrdU antibody (Dako) and FITC-conjugated anti-IgG. The first anti-BrdU antibody was omitted from negative controls. Following antibody staining, the cells were also stained with 20 mg/ml (in PBS) propidium iodide (PI) (Sigma Aldrich Inc.) for 15 min. The DNA content and cell cycling of the cells were analysed using the flow cytofluorimeter.
Immunohistochemical staining
Cells were grown on microscopic cover slips, overlaid with Matrigel (Becton Dickinson), diluted 1:30 in DMEM, and placed inside 12-well plates. They were rinsed in PBS, fixed in cold methanol, and subsequently stained a monoclonal antibody, TUJ-I, against neuronal class III b-tubulin (Covance, Cat. No. MMS-435P), diluted 1:500, and FITC-conjugated goat anti-mouse antibody.
